Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Eli Lilly Stock Just Popped

TheMotleyFool

0 0

Why Eli Lilly Stock Just Popped: https://g.foolcdn.com/editorial/images/857506/woman-injecting-self-in-arm-with-a-glp-1-injector-pen.jpg

Eli Lilly (NYSE: LLY) stock, maker of the Mounjaro and Zepbound GLP-1 weight loss drugs, enjoyed a modest bounce on Monday, rising 3.6% through 10:30 a.m. ET on some good news for Lilly... and some terrible news for rival Novo Nordisk (NYSE: NVO).

Image source: Getty Images.

Novo Nordisk first: This morning, the Danish drugmaker, and inventor of the semaglutide-based Wegovy and Ozempic GLP-1 drugs, announced clinical trial results of its new drug CagriSema (a 50-50 mix of amylin analog cagrilintide and Novo's semaglutide glucagon-like peptide-1 (GLP-1) receptor agonist).

Source Fool.com

Like: 0

LLY

Share